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Abstract
Neurocysticercosis is a frequent parasitic infection of the human brain, occurring in most of the world, and requires imaging
of the brain to diagnose. To determine the burden of disease and to simplify diagnosis, a field-friendly rapid lateral flow (LF)
based antibody screening test was developed. The assay utilizes novel nano-sized up-converting phosphor (UCP) reporter
particles in combination with a portable lightweight analyzer and detects antibodies in serum samples reactive with
bacterial-expressed recombinant (r) T24H, a marker for detecting neurocysticercosis cases. Three sequential flow steps allow
enrichment of antibodies on the Test (T) line and consecutive binding of protein-A coated UCP reporter particles. Antibody
binding was determined by measuring 550 nm emission after excitation of the UCP label with a 980 nm infrared (IR) diode.
Clinical sensitivity and specificity of the assay to detect cases of human neurocysticercosis with 2 or more viable brain cysts
were 96% and 98%, respectively, using a sample set comprised of sera from 63 confirmed cases and 170 healthy parasite-
naı̈ve non-endemic controls. In conclusion: Proof-of-principle, of a rapid UCP-LF screening assay for neurocysticercosis was
demonstrated. The assay utilized bacterial-expressed rT24H as a potential alternative for baculovirus-expressed rT24H.
Performance of the UCP-LF assay was excellent, although further studies need to confirm that bacterial expressed antigen
can entirely replace previously used baculovirus antigen. In addition, the increasing availability of commercial sources for
UCP reporter materials as well as the accessibility of affordable semi-handheld scanners may allow UCP-based bioanalytical
systems for point-of-care to evolve at an even faster pace.
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Introduction
Cysticercosis is a tissue infection caused by hatched onco-
spheres, a larval form of the pork tapeworm Taenia solium.
Although caused by the same pathogen, cysticercosis is different
from the carriage of the adult tapeworm in the intestine (taeniasis).
Cysticercosis is mainly a food borne disease occurring after
exposure to T. solium eggs. Upon ingestion, the eggs release
oncospheres that are able to invade the intestinal wall and
circulate through the bloodstream. This can result in neurocys-
ticercosis, invasion of the nervous system and the formation of
cysts in the brain, which is a major cause of adult acquired epilepsy
and other neurological morbidity in many areas of the world [1,2].
Diagnostic imaging of the central nervous system is required to
confirm the diagnosis and the type of disease [3]. The availability
of a rapid serological diagnosis that targets stage-specific antibod-
ies for human cysticercosis is considered very helpful in control
programs for estimating the burden (sero-prevalence) of disease in
susceptible population groups. A low-cost rapid diagnostic test
could also be applied to determine seroprevalence rates in pigs to
assess interruption of transmission.
Currently, the most useful and the best documented serological
test is the enzyme immunoelectrotransfer blot (EITB), which relies
on antibody reactivity with 7 diagnostic lentil lectin purified
glycoproteins (LLGP) [4]. Recombinant or synthetic peptide
molecules of these proteins are available [5–7]; rT24H corre-
sponding to a 24,000 Da protein of the LLGP extract [7] was
identified as the recombinant protein providing the best sensitivity
and specificity for detecting neurocysticercosis using a multi-
antigen print immunoassay (MAPIA) [8]. Although the EITB test
is the reference standard it is not widely available nor does it exist
in point-of-care or field-friendly formats. In this study we have
developed a LF-based serological test that can be used for point-of-
care (POC) applications and settings with minimal infrastructure
[9,10]. In comparison to an earlier developed immunochromato-
graphy assay based on superparamagnetic particles [11], the assay
described here is fully portable including a lightweight LF strip
analyzer, and is suitable for worldwide shipping and storage at
ambient temperature [12].
Detection devices available for advanced testing, use scanners to
measure reflectance, contrast, color change, or fluorescence
[13,14] and improve clinical sensitivity. Superior sensitivity may
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also permit better detection of antibodies in other biological
matrices, such as saliva, which can be obtained non-invasively
[15,16]. In this respect the potential of up-converting reporter
(UCP) materials for POC diagnostics has been recognized [17,18]
and several studies have demonstrated improved sensitivity and
robustness of the technology [19–23], including use in LF-based
assays [24–29]. Much of the improvement is related to the unique
features of the UCP reporter label, which include emission of
higher energy visual light upon excitation with lower energy
980 nm infrared light [30] by a process called up-conversion. In
contrast to conventional fluorescent labels, applications with UCP
are not hampered from background fluorescence (auto-fluores-
cence). Moreover, the UCP label does not fade, allowing LF strips
to be stored as a permanent record. In addition, interference from
hemolysis of red blood cells is not seen with the UCP detection
system, a problem sometimes encountered in rapid assays using
finger stick blood.
The UCP-LF assay described here detects human antibodies
against the rT24H antigen. This antigen is similar to previously
reported baculovirus produced rT24H antigens [7] but in this study
rT24H produced in a bacterial expression system provides a more
convenient production method. For the current study we have
adapted an earlier described UCP-based antibody test [31,32] for
applications with up-converting nano material ([33–36]) and a
portable lightweight LF strip scanner platform with an integrated
infrared (IR) diode to analyze UCP-LF strips. Results were
compared to previously used reference materials and bench top
readers. The described assay format is suited for POC and on-site
testing applications and integration in microfluidic devices [37–39].
Materials and Methods
Ethics statement
All clinical samples used in this study were collected in previous
studies with specific permission for future use of stored samples.
Samples were anonymized and the study was performed in
compliance with protocols approved by the ethical review boards
of all participating institutes. The defined cysticercosis serum
samples were obtained at the Instituto de Ciencias Neurologicas
(Lima, Peru) and samples from healthy controls were obtained
from Dutch Blood bank donors (Leiden, The Netherlands) and
U.S. residents (Atlanta, Georgia).
Serum samples and patient population
Sera for assay optimization. A series of standards, 0, 1, 2.5
10 and 100 arbitrary units per mL (Units) was constructed from a
pool of 5 serum samples from human cases with confirmed
cysticercosis by dilution in a negative serum pool (combined serum
samples from United States residents with no history of
international travel). The samples contained antibodies that
reacted to the diagnostic proteins in the LLGP-EITB assay [4],
with the 2.5 Units sample representing the lower limit of detection
level. Normal human serum (NHS) was obtained from Innovative
Research (Dunn Labortechnik, Asbach Germany).
Serum panels to determine clinical sensitivity and
specificity. A total of 63 banked serum samples from patients
with confirmed neurocysticercosis were used to validate the assay.
Samples were previously collected by the Cysticercosis Working
Group (CWG) in Peru Lima. The definitive diagnosis of
neurocysticercosis was confirmed by CT or MRI brain imaging
[40] and for this study, we chose samples from patients with 2 or
more viable cysts. A total of 170 serum samples collected in regions
where transmission of cysticercosis does not occur were used to
assess specificity. These samples consisted of a panel of 78 serum
samples assembled from healthy residents of the United States and
a panel of 92 serum samples from blood bank donors in the
Netherlands.
Serum samples with heterologous infections. A set of 80
samples from previous studies [8,11] was tested to evaluate
potential cross reactivity with other worm infections.
Serum samples used to compare baculovirus and
bacterial rT24H antigen. A set of 39 banked serum samples
from previous studies [8,11] was used for a direct comparison of
the baculovirus- and bacterial-expressed antigens in the ELISA
format (see additional Supporting Information).
Dilution of the serum samples. For UCP-LF assays, the
frozen serum samples were thawed and centrifuged for 2 min at
14,000 rpm. The supernatants were the diluted to 2.5% v/v in LF
assay buffer (100 mM HEPES pH 7.2, 270 mM NaCl, 0.5% w/v
Tween-20, 1% w/v bovine serum albumin) and 40 mL of this was
applied to the LF strips (see description of the UCP-rT24H assay).
Expression and purification of recombinant rT24H
The hydrophilic extracellular domain of T24, T24H [6], was
PCR amplified using AmpliTaq Gold DNA polymerase (Perkin-
Elmer Cetus, Foster City, CA) using the following forward and
reverse deoxyoligonucleotide primers: 59-CGC AGA TCT TAT
CGT CAC GAT TTC GTT CGC C-39 and 59-GCG GAA TTC
CGC CGA AGG CCA GAG CGG AAT CCT TC-39,
respectively. In these sequences, the restriction sites used for
cloning (Bgl II and EcoR I, respectively) are underlined. The PCR
amplification protocol and the techniques for directional cloning
into the BamH I and EcoR I sites of a modified pGEX 4T-2 vector
have previously been described [41]. Expression in the modified
vector yielded a recombinant protein with glutathione-S-transfer-
ase (GST) and a thrombin cleavage site on the amino terminus
and a 66 polyhistidine tag and factor Xa cleavage site on the
carboxy terminus. The plasmid was transformed into Escherichia coli
HB101 cells (Promega Corp., Madison, WI), and sequenced with
Author Summary
A field-friendly screening tool to simplify serological
diagnosis of neurocysticercosis was developed. The assay
utilizes a rapid lateral flow based test platform in
combination with unique fluorescent label, up-converting
phosphor (UCP) reporter particles. The UCP reporter
technology uses infrared excitation and emission of higher
energy visible light. Total absence of autofluorescence
provides the label with a distinctive advantage compared
to common fluorescent labels. The developed assay
detects antibodies against an established marker for
detecting neurocysticercosis cases, recombinant T24H. In
this study rT24H was produced by a bacterial expression
system, a less cumbersome method compared to the
previously used baculovirus expression system. With a
sample set comprised of 63 confirmed neurocysticercosis
cases and 170 healthy controls, clinical sensitivity and
specificity were 96% and 98%, respectively. The study
shows proof-of-principle that the designed UCP-rT24H
assay can provide an on-site rapid screening method
utilizing a mobile lightweight scanner and 40 nm yttrium
fluoride UCP particles. A semi-handheld UCP reader and
nano-sized UCP particles performed as good as previously
used ‘research and development’-only tools. Availability of
commercial sources for UCP reporter materials as well as
the accessibility to affordable scanners may allow UCP-
based bioanalytical systems for point-of-care to evolve at
an even faster pace.
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both forward and reverse primers to confirm sequence fidelity and
orientation. Expression of the His tagged protein was performed in
Escherichia coli strain BL21(DE3)pLysS (Agilent Technologies,
LaJolla, CA), grown in LB broth at 37uC, shaking at 225 rpm.
After reaching a culture density of OD600 nm,0.5–0.6, IPTG was
added at a final concentration of 0.2 mM and incubation was
continued for 3 h. The cells were collected by centrifugation (5K,
4uC for 20 min) and the cell pellet was stored at 280uC.
Recombinant protein was purified on a 10 mL GST–Sepharose
4B affinity column as directed by the manufacturer (GE
Healthcare, Piscataway, NJ), and glutathione-eluted material was
dialyzed against PBS (Spectra/Por3; 3,500-Da cutoff; Spectrum
Laboratories, Rancho Dominguez, CA). His-tagged protein was
further purified over a 5 ml Ni2+ affinity column (GE Healthcare)
equilibrated in PBS and elution with a step gradient of 250 mM
imidazole in PBS. After a second dialysis step the purified His-
tagged protein was treated with bovine Factor Xa (approximately
1 U/mg protein; Novagen, San Diego, CA) overnight at room
temperature to remove the His-tag; the cleaved His-tag and
uncleaved proteins were then removed by reapplication onto Ni2+
columns. GST-tagged rT24H (without His tag) was eluted with
2 mM imidazole in PBS at pH 7.2. The purified protein was
dialyzed a third time against PBS prior to storage at 280uC (see
Supporting Information for gel analysis of the purified GST-tagged
protein used to prepare the rT24H Test line of the LF strips).
UCP reporter and LF strip materials
EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide HCL)
and sulfo-NHS (N-hydroxy-sulfosuccinimide) were purchased from
Pierce (Thermo Scientific, Rockford, IL). Protein A (ProtA;
recombinant RPA-50; Repligen, Waltham, MA, USA) was
covalently bound to UCP reporters as described earlier [25,42] in
a ratio of 25 mg/mg for the submicron-sized silica coated and C10-
carboxylated 400 nm Y2O2S:Yb
3+,Tm3+ particles (OraSure Tech-
nologies, Bethlehem, PA, USA; [27,43–45] and 250 mg/mg for
poly(acrylic acid) coated the nano-sized 40 nm NaYF4:Yb
3+,Er3+
UCP particles (Intelligent Materials Solution, Princeton, NJ, USA).
Bovine serum albumin was obtained from Sigma Aldrich (A-2153).
The resulting UCP-ProtA conjugates (1 mg/mL) were stored in a
refrigerator at 4uC and used over a period of 6 months without
notable loss of performance. LF strip materials were obtained from
Merck-Millipore (25 mm, laminated Hi-Flow Plus HF090 nitrocel-
lulose and 1 cm Surewick glass-fiber sample pad) and GE
Healthcare (Whatman #470 absorbent pad). Materials were
compiled on an adhesive plastic backing card (G&L Precision Die
Cutting, San Jose, CA, USA). LF cards were prepared with a Test
(T) line of 200 ng (per 4 mm width) rT24H and a Flow Control (FC)
line of100 ng (per 4 mm width) protein-A according previously
described protocols [25,42] and cut into 4 mm wide LF strips using
a BioDot CM4000 guillotine cutter. A schematic of the LF strip is
shown in Fig. 1. Strips were stored dry in containers with silica.
rT24H ELISA
Microwell plates (Immulon 2 HB) were sensitized with rT24H
antigen (0.6 mg/mL in Tris buffer (0.05 M Tris/HCl pH 8.0,
0.3 M KCl, 2 mM EDTA) for 2 hours at room temperature on a
plate shaker. Following antigen sensitization, the plates were washed
4 times with PBS with 0.3% v/v Tween-20 (PBS-Tween). Plates
were blocked for 30 min with 100 mL of StabilCoatH Immunoassay
Stabilizer (SurModics, East Prairie, MN) on a plate shaker at room
temperature. After removing of the blocking buffer plates were
incubated for 4 hours in a vacuum drying chamber. Dry plates
where then stored inside an aluminum pouch with desiccator at 4uC
until use. Serum samples were diluted 1:50 in PBS buffer with 0.3%
v/v Tween-20 and 5% w/v instant nonfat dry milk powder.
Following 30 minute incubation at room temperature on a plate
shaker, the plate was washed 4 times with PBS- Tween. Protein A
conjugated with horseradish peroxidase (Southern Biotech, Bir-
mingham, AL) was added to each well, 100 mL of a 1:2,000 dilution
in PBS- Tween, and incubated for 30 minutes at room temperature
on a plate shaker. After 4 PBS-Tween washes, 100 ml per microwell
peroxidase substrate TMB (SureBlue, 3, 39, 5, 59 –Tetramethyl-
benzidine, KPL, Gaithersburg, MD) was added and plates were
incubated for 5 minutes at room temperature on a plate shaker. The
peroxidase reaction was stopped by adding 100 mL of 1 M H2SO4
(Analyzed ACS Reagent, J.T. Baker, Phillipsburg, NJ). Plates were
read at A450 nm using a VersaMaxH Kinetic ELISA Microplate
Reader with SoftMaxH Pro v5.4 Software (Molecular Devices
Corporation, Palo Alto, CA).
UCP-rT24H assay
Directly before use, the stock solution of the UCP-ProtA
conjugate was suspended by vortex for 10 sec. The desired
amount of UCP reporter was diluted in LF assay buffer to a final
volume of 100 mL and sonicated (2 cycles of 30 s at 20 kHz and
320 W power with 15 s power off between, in a ultrasonic water
bath, Biorupter Diagenode) to homogenize potential aggregates.
UCP reporter was further diluted in assay buffer to 7.15 ng/mL for
both the 400 nm and 40 nm particles. The UCP-rT24H assay
consists of three consecutive flow (CF) steps: 40 mL of diluted
sample (2.5% v/v serum sample in assay buffer), followed by a
20 mL wash step (assay buffer), and finally 70 mL UCP-ProtA
conjugate (500 ng), following the earlier described protocol for
antibody detection [31] with a 2 min pause after flow step 1
(sample) and a 5 min pause after flow step 2 (wash). Chromatog-
raphy was allowed to continue for at least 30 min or until strips
were completely dry. LF strips that are still wet upon scanning may
generate a lower emission signal; if needed, LF strips were dried in
an oven after a minimum flow time of 30 min. LF strips were
scanned by using a multi-strip scanner, modified Fluorocount
Packard reader [25,43] and the a custom ESEQuant LFR
(QIAGEN Lake Constance, Stockach, Germany) adapted for
excitation at 980 nm and emission at 550 nm. The latter reader is
a small, lightweight reader suited for single strip scanning; it is also
referred to as UCP-Quant [12,42]. Emission signals measured at
the T and FC line were measure in relative fluorescent units (RFU,
Packard) or in mV (UCP-Quant); Ratio values (calculated by
dividing T by FC) were used to analyze test results rather than
using T signals only [43].
Data analysis
Peak areas for T and FC line were calculated by the reader-
specific software. The Packard reader used OTI-Connect (version
1.1.23, OraSure Technologies) and the UCP Quant reader used
Lateral Flow Studio (version 3.03.05, QIAGEN Lake Constance).
Data were entered into Excel, T line signals were divided by the
FC line signals of each individual strip delivering the Ratio (T/FC)
value as described previously [43]. Additionally, to express data as
a normalized assay value (NAV) relative to the highest quality
control sample, T line signals or Ratio values were presented as the
relative value (in percentage) compared to the highest value
obtained with the 100 Units standard in a particular experiment.
Results
UCP-rT24H assay conditions
Serum sample load. The performance of the UCP-rT24H
assay was first assessed with a set of sera with reactivities ranging
POC Antibody Test for Neurocysticercosis
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from 1 to 100 Units as determined by ELISA. The 2.5 Units
sample represents the targeted lower limit of detection (LLOD), a
sample with low antibody titer. The general protocol applied for
the UCP-LF assay used for the majority of the experiments in this
study, implied a dilution of sera in assay buffer such that 1 mL
undiluted serum was delivered to the LF strips during the first flow
step of the CF protocol (Fig. 1). The assay seemed to perform
similarly to previously described UCP-CF antibody assays
indicating high degree of flexibility for sample input [31,32,46].
Amount of rT24H antigen on the test (T-)line. Often, the
major production cost of LF-based assays is linked to the capture
antigen on the T-line. The density (amount) of specific-antigen
must be sufficient to capture the target molecules yet not in excess
so to lead to poor immobilization of the capture antigen on the LF
strip, thereby resulting in the unexpected loss of signal. For the
UCP-rT24H assay the T-line is comprised of purified rT24H.
Fig. 2A shows the result of a typical experiment, indicating lower
T-signal due to release when using 400 ng of rT24H antigen (per
4 mm width). All assays were performed with the same amount of
UCP label, and T-signal values were normalized to the highest T-
signal measured with the 100 Units sample; achieved with the LF
strips containing an rT24H density of 100 ng, the 200 ng strips
scored only a slightly lower signals. Differences become more
pronounced when looking at normalized Ratio values (T-line
signal divided by FC-line signal). An optimum around the targeted
lower limit of detection (LLOD) of 2.5 Units with LF strips
containing a T-line comprised of 200 ng rT24H seems apparent.
A large difference between the zero and the sample indicative for
the LLOD is essential to determine a solid assay cutoff threshold.
The relative differences in Ratio values determined for the 0 and
2.5 Units samples were a factor of 2.16, 5.20 and 3.32 for the 100,
200 and 400 ng strips, respectively; corresponding A450 ELISA
values (not shown) indicated a factor of 2.86. These values may
differ when using differently sized UCP particles; the experiment
shown in Fig. 2 was performed with 400 nm particles, similar
results were observed with the 40 nm particles. An additional
constraint to consider is the sensitivity of the applied UCP-LF strip
scanner, which is the lowest UCP signal that can be measured with
a given UCP reader. Further reduction of the amount rT24H
(down to 25 ng) decreased T-line signals such that the 2.5 Units
standard sample was not detectable with the ESE Quant reader
(results not shown).
Submicron- versus nano-sized UCP particles. The po-
tential of a new source of UCP particles, nano-sized 40 nm
particles, was tested on LF strips containing T-lines with 200 ng
rT24H antigen. In these experiments the 1 Unit standard sample
was included rather than the 2.5 Units standard to allow
exploration below the targeted LLOD, set a 2.5 Units. Four
standard samples (0, 1, 10 and 100 Units) were diluted 10- and
100-fold in NHS and analyzed with UCP-T24H assay using UCP
conjugates made with the 40 nm and 400 nm reporter particles.
Fig. 3 shows the result of an experiment performed in triplicate.
Assay values were normalized to the highest Ratio value obtained
with the 100 Units sample. Results indicate that both particle sizes
appear to allow discrimination of the 1 Unit standard. However,
the relative difference between the negative control (0 Units) and 1
Unit sample is minimal (a factor of 1.54 and 1.57 for 40 and
400 nm, respectively) and may be difficult to reproduce when
experiments are performed as single measurements. Dilution of
the original standards in NHS had some effect on the background
signal (Fig. 3), indicating that different negative sera will show
some variability and as such impact the cutoff threshold of the
assay. Overall, the applied test conditions (500 ng UCP-conjugate
per strip) seem to be somewhat in favor of the 40 nm nano-
particles. This is demonstrated by the increase of the signal
strength observed for 1 to 10 Units for the 40 nm particles: a factor
Figure 1. The UCP-rT24H assay. Panel A: Schematic of the UCP-rT24H LF strip: Test line (T) 200 ng rT24H and Flow Control line (FC) 100 ng
protein-A. Panel B: The LF protocol for antibody detection (in previous publications referred to as consecutive flow, CF [31] with the three sequential
flow steps indicated. Panel C and D: Transmission electron microscopy images of respectively, the 400 nm [44] and 40 nm (by courtesy of J. Collins)
UCP materials. Panel E and F: Image of respectively, the modified Fluorocount Packard benchtop reader for scanning multiple LF strips and the
portable, custom adapted, lightweight ESEQuant LFR reader.
doi:10.1371/journal.pntd.0002944.g001
Figure 2. Optimization of rT24H capture antigen load of the T-
line. Performance of the UCP-rT24H assay with a standard reference
panel of cysticercosis serum samples. The T-line signal (panel A) and
Ratio value (panel B) indicate an optimum for the 2.5 Units sample with
the 200 ng rT24H Test. Assay results are presented as normalized assay
values, as percentage of the highest signal obtained with the 100 Units
standard.
doi:10.1371/journal.pntd.0002944.g002
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of 7.69 versus 3.75 increase for the 40 and 400 nm particles,
respectively. The 500 ng UCP particles per LF strip matched well
with the lightweight UCP-Quant strip reader available for the
analysis. Note that the submicron-sized 400 nm UCP particles
applied in other UCP-LF assays [31,46] were generally used at
100 ng per strip; when comparing equal mass of the 40 and
400 nm UCP particles striped on LF strips, the intensity of
emission did not show a relevant difference (results not shown).
Cutoff threshold and clinical parameters
The above established UCP-LF assay conditions used to
validate the UCP-rT24H neurocysticercosis antibody assay
involved the use of 4 mm width LF strips with a T-line of
200 ng rT24H and the addition of the equivalent of 1 mL
undiluted serum sample and 500 ng UCP protein-A coated
reporter particles. Testing of the clinical samples was performed in
parallel with using both types of UCP reporter particles: The
40 nm NaYF4:Yb
3+,Er3+ particles with poly(acrylic acid) surface
and the 400 nm sized Y2O2S:Yb
3+,Tm3+ particles with a silica
coated carboxyl-functionalized surface.
Cutoff threshold. In order to assess clinical specificity, the
assay cutoff threshold was evaluated with two sets of sera samples
from healthy individuals following a protocol as described earlier
[47] implying the definition of a low and high specificity cutoff
threshold. The UCP-rT24H Ratio values were determined for
both sample sets (92 Dutch blood donors and 78 healthy U.S.
residents) using both types of UCP particles. Table 1 summarizes
the determined values; the low specificity cutoff threshold was
defined as the average Ratio value plus two times the standard
deviation and the high specificity cutoff threshold was defined as
the highest Ratio value in the control group plus two times the
standard deviation. Samples generating Ratio values below the low
specificity cutoff will be considered antibody negative with the
UCP-rTH24 test, samples above the high specificity cutoff will be
considered antibody positive. To determine the most likely
classification of samples generating signals between the low and
high specificity cutoff, the determined threshold values need to be
evaluated with a large, statistically relevant, set of confirmed
positives. The significant difference in cutoff values when using
NaYF or YOS UCP particles is a technical issue that can be
regulated by changing assay conditions (e.g. the amount of UCP
particles or the amount of rT24H on the Test line). The observed
smaller difference in cutoff value between the two sets of healthy
individuals tested with the same UCP particles may indicate an
effect based on cultural behavior and/or ethnicity.
Single blinded assay validation. Validation of the assay
was performed using the sera from 63 cases of neurocysticercosis
randomly arranged between the set of 78 serum samples from
healthy U.S. residents. The resulting 141 samples were tested with
both types of UCP particles in a single blind experiment. Obtained
UCP-rT24H Ratio values were plotted against the corresponding
rT24H ELISA OD450 values (Fig. 4) showing a good correlation
between the UCP and ELISA. The test conditions for the ELISA
were set for best resolution in the low reactive range, implying a
maximum A450 nm value of 4 and thus no discrimination between
highly reactive samples. As observed when testing the cutoff
threshold samples, the Ratio values determined with the 40 nm
NaYF UCP particles on average differed by a factor of ,4
Figure 3. Lower limit of detection with sub-micron and nano-sized UCP particles. Analysis (in triplicate) of standard reference samples
(diluted in NHS) with an infection grade of 0, 1, 10 and 100 Units analyzed with the UCP-rT24H assay utilizing submicron-sized 400 nm UCP particles
(panel A) and 40 nm nano-sized UCP particles (panel B). Assay results are presented as normalized assay values, as percentage of the highest signal
obtained with the 100 Units reference.
doi:10.1371/journal.pntd.0002944.g003
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compared to the Ratio values determined with the 400 nm YOS
UCP particles. Qualitatively both type of UCP particles seem to
perform quite similarly, whereas quantitatively the 40 nm NaYF
UCP particles seem to correlate somewhat better with the ELISA.
Fig. 4C, a scatter plot of the results obtained with the two types of
UCP particles, shows the Spearman correlation (R2 is 0.90) of the
Ratio values by rank order. The relatively large scattering of points
in the lower range is directly linked to the low Ratio values
measured for the non-reactive samples (indicated by the grey box).
Clinical sensitivity and specificity. Application of the low
and high specificity thresholds (Tab. 1) as determined with the 170
healthy controls indicated a number of UCP-rT24H false positives
and false negatives. A sample was classified false positive (FP) when
it was part of the set of healthy controls with a Ratio value score
above the cutoff threshold; a sample was classified as a false
negative (FN) when it was part of the set of defined cysticercosis set
(with 2 or more cysts identified by imaging). When using both low
and high specificity thresholds, an indecisive (IND) or potentially
positive group can be identified from samples scoring Ratio values
between the low and high specificity threshold, Table 2. By
definition, at 100% clinical specificity (Sp) all 170 healthy control
samples should score a Ratio value below the cutoff threshold. For
the assay with the 40 nm NaYF UCP particles, for example, this is
achieved when using the high specificity threshold determined for
the U.S. resident group. Clinical sensitivity (Sn) of the assay then
drops to 85%; for the 400 nm YOS UCP particles at 100%
specificity, the sensitivity is 89%. The highest sensitivity, obtained
when applying the low specificity threshold determined for the
Dutch blood bank donors, is 98% with a specificity of 88%. The
actual required cutoff threshold is depending of the clinical
sensitivity and specificity required demanded for this assay; in this
respect the area of receiver operating characteristic (ROC) curves
of the UCP-rT24H indicate an area of 0.99 for both types of UCP
particles. In this particular test the low specificity threshold
determined for the U.S. resident group seems to deliver acceptable
sensitivity/specificity levels of 96%/98% (Youden’s index,
J = 0.933) and 94%/98% (J = 0.919) for the 40 and 400 nm
UCP particles, respectively. For both particles, these numbers
imply a positive and negative predictive value of 94% and 98%,
respectively. With the ELISA 96% sensitivity is achieved with 94%
specificity (J = 0.898). These numbers indicate at least equivalent
performance of the UCP-rT24H assay as compared to the ELISA.
Moreover, results show that in consecutive flow based assays [31]
the 40 nm NaYF UCP are a good alternative for the 400 nm YOS
UCP particles.
Heterologous infections. A challenging set of serum sam-
ples from individuals with other parasitic infections was tested with
the 40 nm NaYF UCP particles to evaluate cutoff threshold and
specificity. The set of 80 samples amongst others included serum
samples from individuals infected with Hymenolepis nana (dwarf tape
worm, n = 8), Trichinella spiralis or Wuchereria bancrofti (round worms,
n = 15), long-, liver-, or intestinal-flukes (n = 11), Schistosoma species
(blood-flukes, n = 20) and samples from individuals carrying mixed
(worm) infections. Stool samples did not contain T. solium eggs or
proglottids. Two Schistosoma mansoni samples and one T. spiralis
sample were reactive with a Ratio signal equivalent to the 20 U
standard. One H. nana and one P. westermani showed a low
response, with a Ratio value between the 2.5 and 5 U standard.
Assuming that the five reactive samples are false positives (note
that involved individuals have not been examined for neurocys-
ticercosis incidents), clinical specificity in this group of 80 is 94.1%.
When including the Dutch donor and U.S. residents control
samples and using the low specificity cutoff Ratio value as
determined with the 40 nm NaYF UCP particles for the 78 U.S.
residents (Table 1), clinical specificity in the combined negative
group (n = 250) is 96.5%; TN = 250, FP = 4+5.
Performance of the lightweight portable LF strip reader
The use of a commercially available LF strip reader platform
(ESEQuant LFR) custom adapted with UCP capability [12,32,42]
was evaluated for its use in applications with nano-sized (40 nm)
NaYF UCP reporter particles. A total of 258 LF strips obtained
from testing clinical samples and various standards series with
40 nm UCP particles were re-analyzed on the adapted ESEQuant
LFR reader referred to as UCP Quant. Fig. 5 shows the correlation
of the results obtained with the lightweight UCP Quant reader and
the multi-strip Packard reader. Ratio values are used rather than
actual peak areas of the T and FC lines as the determined ratio
amongst others can manage device related variations, e.g. difference
caused by variation in the performance of different IR light-emitting
diode. This allowed direct inter assay comparison of ratio value
results when the same type of reader and software is used. In panel
A, the Ratio value determined with both readers indicates excellent
agreement with a linear correlation coefficient R2 = 0.96. Focusing
on the lower Ratio value range indicates a cluster of assays results
below the cutoff threshold determined for U.S. residents using the
multi-strip Packard reader, 0.109 (Tab. 1). This cluster includes
most healthy control samples as also indicated in panel B showing
the excellent Spearman correlation (R2 = 0.96) by Ratio value rank
order (low specificity area indicated in grey). The UCP-Quant
reader results would not change the outcome of the single blinded
clinical validation experiment and thus is an appropriate reader in
combination the 40 nm NaYF in the here described CF assay
format with 500 ng UCP particles per test. Moreover, even though
different software is used to calculate T and FC peak areas and
although the Packard reader is equipped with a photo multiplier
and a higher power IR laser, the actual ratio values measured with
both readers differed only slightly.
Table 1. Cutoff threshold of the UCP-rT24H assay.
92 Dutch blood donors 78 U.S. residents
40 nm NaYF 400 nm YOS 40 nm NaYF 400 nm YOS
Ratio: Average Value (AV) 0.029 0.008 0.046 0.009
Ratio: Highest Value (HV) 0.110 0.026 0.186 0.033
Standard Deviation (SD) 0.021 0.005 0.032 0.007
Low specificity cutoff: AV+2SD 0.070 0.019 0.109 0.023
High specificity cutoff: HV+2SD 0.151 0.037 0.231 0.047
doi:10.1371/journal.pntd.0002944.t001
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Figure 4. Comparison of the UCP-rT24H assay with the ELISA. Single blind evaluation with 141 clinical samples. Comparison of Ratio values
obtained with the 40 nm sized NaYF UCP particles (panel A) and the 400 nm sized YOS UCP particles (panel B) with the ELISA OD450 values. Note that
both insets show the results using a linear scale and the x-axis limited to 0.4 and 1.0, respectively. Spearman ranking (panel C) of the UCP-rT24H Ratio
values obtained with both UCP particles. The grey box indicates samples scoring values below the low specificity threshold (U.S. resident control
group).
doi:10.1371/journal.pntd.0002944.g004
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Discussion
This study describes the development of a new low cost
screening tool to simplify the diagnosis of neurocysticercosis on-site
and at POC facilities, a helpful tool in control programs to
estimate sero-prevalence. The serological test builds on a
previously described method using LF and the unique UCP
reporter label. Evaluation of the new UCP-rT24H test with a set of
clinical samples indicated excellent clinical parameters comparable
to ELISA. Application of new nano-sized UCP reporter label and
a lightweight strip analyzer, both from easily accessible sources,
demonstrated equal performance to previously used ‘research and
development’-only materials.
The applied UCP-LF format (referred to as consecutive flow,
CF) was developed previously to allow simultaneous (multiplex)
detection of antibodies against different infectious diseases [31].
This was achieved using LF strips with multiple distinct disease/
pathogen specific capture lines and the sequential flow of a clinical
sample, followed by assay buffer and a flow of an Ig-specific UCP
conjugate. Separation of the sample flow from the UCP-ProtA
reporter flow allows the anti-rT24H specific antibodies to bind and
enrich at the T line while other human immunoglobulins (Ig’s) will
flow past the T-line towards the FC line and absorbent pad, before
interaction with the UCP-ProtA reporter. As a result, anti-rT24H
specific antibodies do not need to compete with the surplus of
other human Ig’s for binding to the relatively limited number of
protein A molecules on the UCP reporter. Detection of antibodies
indicating neurocysticercosis is another example showing the
applicability of UCP-CF assay format for antibody detection. The
described UCP-rT24H assay demonstrated excellent feasibility for
detecting neurocysticercosis cases.
A notable difference of the new test is the use of bacterial
expressed recombinant antigen rT24H. Currently, the availability
of rT24H cysticercosis antigen is limited as a consequence of the
relatively complex production method requiring a baculovirus
expression system. The initial results shown here appear to
validate the use of the bacterial rT24H recombinant antigen, but
this will require further analysis. Moreover, further optimization is
needed to reproducibly identify sera from patients with single cyst
infections. Important also are specificity issues; do LF strips with
the bacterial produced rT24H perform similar to LF strips with a
capture line of baculovirus produced rT24H? In this study, U.S
residents and Dutch blood donors were used as control group for
confirmed neurocysticercosis cases from Peru because a defined
control group from the endemic area was not available. It is
obvious that the use of a non-endemic control group to determine
assay cutoff values is not optimal and this may require further
validation. However, the performance of the assay with a set of
samples with heterologous worm infections demonstrated clinical
specificity values in the same range as determined for the two non-
endemic healthy control groups. A further evaluation of the
current assay should also include appropriate (confirmed neuro-
cysticercosis negative) endemic controls as well as taeniasis cases.
The performance of the assay with the current set of clinical
samples was comparable to the more established methods EITB-
LLGP and the in-house ELISA. Moreover, results obtained with
the UCP-rT24H assay do not appear to differ from the previously
described ELISA alternative, the MICT assay utilizing baculovirus
rT24H [11]. The MICT test however does not include a portable
reader to allow analysis of the assay remote from the laboratory.
With this study we have shown proof-of-principle for use of
(potential) commercially available UCP reporter materials and
analyzer equipment. The production process (thermal composition
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Figure 5. Comparison of the UCP Quant with the Packard reader. Panel A: A scatter plot of UCP-rT24H Ratio values obtained from 257 LF
strips calculated. Specificity cutoff thresholds calculated for the U.S. residents control group (Table 1) are indicated. Panel B: A scatter plot showing
the samples ranked on UCP-rT24H Ratio value (Spearman rank correlation). The grey box indicates samples scoring values below the low specificity
threshold (U.S. residents).
doi:10.1371/journal.pntd.0002944.g005
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NaYF particles is well described and easier to control [36].
Brightness of UCP particles (visible emission upon IR excitation) is
directly related to the volume of the particle; however, per mass
equivalent, the current 40 nm NaYF particles emit approximately
the same amount of light (upon IR excitation) as the 400 nm YOS
particles. In general, smaller particles will need fewer capture
molecules to bind to the Test line of a LF strip. Whether the
current size and shape is optimal can be determined empirically as
the UCP production process allows a well-controlled particle size
and morphology [36]. Additionally, coating of the current 40 nm
particles with an inert silica layer instead of the current poly
(acrylic acid) polymer surface may further improve UCP particle
performance in LF-based assays. A robust coating is also of
importance when moving towards dry assay reagents [12].
The two different control groups of healthy individuals used in
this study to validate the assay suggested that differences in cultural
behavior and/or ethnicity may affect analytical sensitivity (the
lower limit of detection). However, as these difference between
Europeans and U.S. residents probably are minimal, the observed
difference may also be a consequence of using banked serum
samples that were collected, pre-treated (serum preparation) and
stored at different locations. Also, in order to make this test
conveniently suitable for on-site use or point-of-care testing the
assay should allow the use of fresh whole blood finger stick
samples. The use of finger-stick blood in UCP-LF based assays is
part of ongoing research for the quantitative testing of trough
levels of immunotherapeutics [32]. Antibody testing using saliva as
a non-invasive specimen type is also an attractive area for
exploration when aiming at field testing, but this will require a
comprehensive reanalysis of the cutoff [15].
In conclusion: We have demonstrated that an earlier described
rapid UCP-CF serological assay format can be applied to detect
antibodies produced during neurocysticercosis. The assay performed
well with LF strips containing an antibody-capture line comprised of
bacterial expressed recombinant T24H, a convenient alternative for
current rT24H produced with a baculovirus expression system. The
new 40 nm NaYF UCP particles and the custom adapted
lightweight semi hand-held LF strip reader are appropriate
alternatives for earlier used and difficult to access reporter material
and more expensive laboratory-based scanning equipment.
Supporting Information
Figure S1 Purity of the bacterial T24H fusion protein.
The bacterial expressed T24H used in the current UCP-LF assay
is a GST-T24H fusion protein with a molecular weight of 34 kDa.
To assure production of sufficient full-length T24H, it was
expressed as a double-tagged protein, with a His tag at the C-
terminus and the GST tag at the N-terminus. After a two-step
purification protocol involving both tags, the His-tag was removed
but the GST-tag was retained. The GST-tag (24 kDa) allowed
convenient imagining of the GST-T24H fusion protein on a
Coomassie Brilliant Blue (CBB) stained denaturing gel (SDS-
PAGE); the 10 kDa T24H by itself does not stain well due to a low
percentage of aromatic amino acids. The GST tag does not
interfere with the specificity of the T24H assay and improved
binding of the antigen to the LF strip. Purity of the GST-T24H
fusion protein (F, 34 kDa) was analyzed using CBB-stained SDS-
PAGE. The major part of the purified material is full length GST-
T24H 34 kDa fusion protein (F, lane 2); the less abundant smaller
bands indicate some degradation of the C-terminus of the T24H.
The presence of the 10 kDa T24H (T) fragment was demonstrated
after thrombin cleavage of the 24 kDa GST tag (G); left and right
lanes (lanes 1 and 4) contain molecular weight (MW) markers.
After thrombin cleavage a single 24 kDa band is evident (G, lane
3), the T24H fragment (T, lane 3) is visible as a less distinct and
poorly stained band.
(TIF)
Figure S2 ELISA comparison of bacterial-expressed
rT24H with reference antigen. To validate the performance
of the bacterial expressed T24H (GST-T24H fusion protein), a set
of 39 serum samples (including 13 confirmed cysticercosis and
taeniasis cases) were analyzed by ELISA utilizing both the new
bacterial-expressed rT24H and the reference antigen, rT24H
produced using the baculovirus production system. In panel A, the
plot of ELISA A450 values of both rT24H preparations. Panel B
shows the performance around the theoretical cutoff thresholds
(indicated by the dotted lines, experiment performed in singlet). In
panel C the Spearman correlation with samples ranked by order of
their A450 value; indicated cutoff thresholds (dotted lines) correlate
with the thresholds shown in panel B. Based on determined assay
value (ELISA), results demonstrate a high correlation indicating
that both antigens performed similarly for this set of samples.
(DOCX)
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